Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

Mauro Loi; Ariane Dunant; Sahar Ghith; Almudena Maria Cascales-Garcia; Chafika Mazouni; Barbara Pistilli; Marie Christine Mathieu; Eric Deutsch; Rodrigo Arriagada; Sofia Rivera

doi:10.1080/07357907.2018.1564325

Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

Mauro Loi, Ariane Dunant, Sahar Ghith, Almudena Maria Cascales-Garcia, Chafika Mazouni, Barbara Pistilli, Marie Christine Mathieu, Eric Deutsch, Rodrigo Arriagada, Sofia Rivera

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Purpose: To assess predictors of outcome in a cohort of Inflammatory Breast Cancer (IBC) patients receiving induction chemotherapy followed by local treatment. Methods: We retrospectively reviewed 95 non-metastatic IBC patient files. Results: Complete clinical response (cCR) was obtained in 15 (16%) patients. Median follow up was 13.4 years (IC95%: 10.4–14.6). Loco-regional control (LC), disease-free survival (DFS), and overall survival (OS) at 5 years were 85%, 41%, and 55%, respectively; cCR was associated with better DFS and OS in multivariate analyses adjusted for age (p = 0.02). Conclusions: Clinical response to upfront chemotherapy predicts the outcome of patients affected by IBC.

Original language	English
Pages (from-to)	29-38
Number of pages	10
Journal	Cancer Investigation
Volume	37
Issue number	1
DOIs	https://doi.org/10.1080/07357907.2018.1564325
Publication status	Published - 2 Jan 2019

Keywords

Breast cancer
chemotherapy
outcome research
radiation oncology

Access to Document

10.1080/07357907.2018.1564325

Cite this

@article{8a2656080aeb4f589c7ae06fa4d59965,

title = "Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer",

abstract = "Purpose: To assess predictors of outcome in a cohort of Inflammatory Breast Cancer (IBC) patients receiving induction chemotherapy followed by local treatment. Methods: We retrospectively reviewed 95 non-metastatic IBC patient files. Results: Complete clinical response (cCR) was obtained in 15 (16%) patients. Median follow up was 13.4 years (IC95%: 10.4–14.6). Loco-regional control (LC), disease-free survival (DFS), and overall survival (OS) at 5 years were 85%, 41%, and 55%, respectively; cCR was associated with better DFS and OS in multivariate analyses adjusted for age (p = 0.02). Conclusions: Clinical response to upfront chemotherapy predicts the outcome of patients affected by IBC.",

keywords = "Breast cancer, chemotherapy, outcome research, radiation oncology",

author = "Mauro Loi and Ariane Dunant and Sahar Ghith and Cascales-Garcia, {Almudena Maria} and Chafika Mazouni and Barbara Pistilli and Mathieu, {Marie Christine} and Eric Deutsch and Rodrigo Arriagada and Sofia Rivera",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Taylor & Francis Group, LLC.",

year = "2019",

month = jan,

day = "2",

doi = "10.1080/07357907.2018.1564325",

language = "English",

volume = "37",

pages = "29--38",

journal = "Cancer Investigation",

issn = "0735-7907",

number = "1",

}

TY - JOUR

T1 - Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

AU - Loi, Mauro

AU - Dunant, Ariane

AU - Ghith, Sahar

AU - Cascales-Garcia, Almudena Maria

AU - Mazouni, Chafika

AU - Pistilli, Barbara

AU - Mathieu, Marie Christine

AU - Deutsch, Eric

AU - Arriagada, Rodrigo

AU - Rivera, Sofia

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Purpose: To assess predictors of outcome in a cohort of Inflammatory Breast Cancer (IBC) patients receiving induction chemotherapy followed by local treatment. Methods: We retrospectively reviewed 95 non-metastatic IBC patient files. Results: Complete clinical response (cCR) was obtained in 15 (16%) patients. Median follow up was 13.4 years (IC95%: 10.4–14.6). Loco-regional control (LC), disease-free survival (DFS), and overall survival (OS) at 5 years were 85%, 41%, and 55%, respectively; cCR was associated with better DFS and OS in multivariate analyses adjusted for age (p = 0.02). Conclusions: Clinical response to upfront chemotherapy predicts the outcome of patients affected by IBC.

AB - Purpose: To assess predictors of outcome in a cohort of Inflammatory Breast Cancer (IBC) patients receiving induction chemotherapy followed by local treatment. Methods: We retrospectively reviewed 95 non-metastatic IBC patient files. Results: Complete clinical response (cCR) was obtained in 15 (16%) patients. Median follow up was 13.4 years (IC95%: 10.4–14.6). Loco-regional control (LC), disease-free survival (DFS), and overall survival (OS) at 5 years were 85%, 41%, and 55%, respectively; cCR was associated with better DFS and OS in multivariate analyses adjusted for age (p = 0.02). Conclusions: Clinical response to upfront chemotherapy predicts the outcome of patients affected by IBC.

KW - Breast cancer

KW - chemotherapy

KW - outcome research

KW - radiation oncology

UR - http://www.scopus.com/inward/record.url?scp=85060237987&partnerID=8YFLogxK

U2 - 10.1080/07357907.2018.1564325

DO - 10.1080/07357907.2018.1564325

M3 - Article

C2 - 30656969

AN - SCOPUS:85060237987

SN - 0735-7907

VL - 37

SP - 29

EP - 38

JO - Cancer Investigation

JF - Cancer Investigation

IS - 1

ER -

Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this